Xtalks — The Life Science Community™, Online webinar
2026-10-26
Bispecific antibodies have emerged as a rapidly growing biologic modality that can engage two distinct biological targets within a single molecule. Their unique mechanisms of action have created new opportunities in oncology, immunology and other therapeutic areas, enabling treatment strategies that may not be achievable with traditional monoclonal antibodies. However, the same structural complexity that drives their therapeutic potential also introduces significant development and manufacturing challenges. This webinar explores the critical considerations involved in developing and manufacturing bispecific antibodies, from early-stage process development through commercial scale-up. The featured speaker will examine how antibody design influences manufacturability, why correct heavy and light chain pairing is essential and the strategies development teams use to promote formation of the desired molecular structure while minimizing product variants. The session will also examine the role of cell line development, analytical characterization and process optimization in supporting product quality and consistency. Focus will be placed on downstream purification challenges, including the removal of mispaired and incomplete antibody species and the design of chromatography-based purification workflows capable of achieving clinical and commercial purity requirements. As bispecific antibody programs advance toward larger manufacturing scales, maintaining product consistency becomes increasingly important. The webinar will discuss how process parameters can influence variant distribution and how robust process characterization helps ensure reliable performance during scale-up. The featured speaker will discuss a real-world example of how purification strategies were optimized to improve product purity and support successful transition into clinical manufacturing. Register for this webinar to learn how bispecific antibodies can be developed and manufactured to address purification, product consistency and scale-up challenges.
|